ADMA Quote, Financials, Valuation and Earnings

Emergent BioSolutions has a net margin of 95.19% compared to ADMA Biologics's net margin of -16.54%. ADMA Biologics's return on equity of 93.41% beat Emergent BioSolutions's return on equity of -35.42%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 41.5%. On the other hand Emergent BioSolutions has an analysts' consensus of $13.50 which suggests that it could grow by 215.42%. Given that Emergent BioSolutions has higher upside potential than ADMA Biologics, analysts believe Emergent BioSolutions is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Emergent BioSolutions has a beta of 2.141, suggesting its more volatile than the S&P 500 by 114.124%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Emergent BioSolutions pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are smaller than Emergent BioSolutions quarterly revenues of $189.3M. ADMA Biologics's net income of $111.9M is higher than Emergent BioSolutions's net income of -$31.3M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Emergent BioSolutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.17x versus 0.23x for Emergent BioSolutions. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of 95.19% compared to ADMA Biologics's net margin of -1816.75%. ADMA Biologics's return on equity of 93.41% beat Ocugen's return on equity of -171.04%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 41.5%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 1058.2%. Given that Ocugen has higher upside potential than ADMA Biologics, analysts believe Ocugen is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are larger than Ocugen quarterly revenues of $764K. ADMA Biologics's net income of $111.9M is higher than Ocugen's net income of -$13.9M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.17x versus 38.94x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of 95.19% compared to ADMA Biologics's net margin of -283.27%. ADMA Biologics's return on equity of 93.41% beat Ocular Therapeutix's return on equity of -62.66%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 41.5%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 190.7%. Given that Ocular Therapeutix has higher upside potential than ADMA Biologics, analysts believe Ocular Therapeutix is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.133%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. ADMA Biologics's net income of $111.9M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.17x versus 14.95x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 95.19% compared to ADMA Biologics's net margin of 21.57%. ADMA Biologics's return on equity of 93.41% beat TG Therapeutics's return on equity of 12.81%.

ADMA Biologics has a consensus price target of $25.27, signalling upside risk potential of 41.5%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 20.96%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.

ADMA Biologics has a beta of 0.527, which suggesting that the stock is 47.277% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $117.5M, which are larger than TG Therapeutics quarterly revenues of $108.2M. ADMA Biologics's net income of $111.9M is higher than TG Therapeutics's net income of $23.3M. Notably, ADMA Biologics's price-to-earnings ratio is 21.78x while TG Therapeutics's PE ratio is 253.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.17x versus 16.93x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.